Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., a leading global player in the pharmaceutical industry, is headquartered in the United States. Founded in 1885, the company has established a strong presence in major operational regions, including Europe, Asia, and Latin America. Specialising in human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing, Boehringer Ingelheim is renowned for its innovative therapies and commitment to research and development. The company’s core products encompass a range of prescription medications, particularly in the fields of respiratory diseases, cardiovascular health, and oncology. Boehringer Ingelheim's unique approach to drug development and patient care has positioned it as a trusted name in the industry, with notable achievements in advancing treatment options and improving patient outcomes. With a focus on sustainability and social responsibility, Boehringer Ingelheim continues to make significant strides in enhancing global health.
DitchCarbon Score
How does Boehringer Ingelheim Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim Pharmaceuticals, Inc.'s score of 26 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boehringer Ingelheim Pharmaceuticals, Inc.'s reported carbon emissions
Boehringer Ingelheim Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year. As a current subsidiary, it inherits its climate commitments and emissions data from its parent organisation, Boehringer Ingelheim. Despite the absence of specific emissions figures, the company is engaged in various climate initiatives, although no specific reduction targets or achievements have been documented. The lack of detailed emissions data and reduction initiatives suggests that Boehringer Ingelheim Pharmaceuticals, Inc. may still be in the process of establishing its climate strategy or reporting framework. As part of its corporate family, Boehringer Ingelheim Pharmaceuticals, Inc. aligns with broader industry standards and practices, which may include commitments to sustainability and emissions reduction, but specific details are not available at this time.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boehringer Ingelheim Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
